Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
InflaRx N.V is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. InflaRx N-V employs 43 staff and has a market cap (total outstanding shares value) of USD0.00.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$2.98 - USD$9.70 |
---|---|
50-day moving average | USD$5.11 |
200-day moving average | USD$4.77 |
Wall St. target price | USD$10.62 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-2.08 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -20.39% |
Return on equity TTM | -36.43% |
Profit margin | 0% |
Book value | $7.20 |
Market capitalisation | USD$194.6 million |
TTM: trailing 12 months
There are currently 429,991 InflaRx N-V shares held short by investors – that's known as InflaRx N-V's "short interest". This figure is 8% down from 467,149 last month.
There are a few different ways that this level of interest in shorting InflaRx N-V shares can be evaluated.
InflaRx N-V's "short interest ratio" (SIR) is the quantity of InflaRx N-V shares currently shorted divided by the average quantity of InflaRx N-V shares traded daily (recently around 443289.69072165). InflaRx N-V's SIR currently stands at 0.97. In other words for every 100,000 InflaRx N-V shares traded daily on the market, roughly 970 shares are currently held short.
However InflaRx N-V's short interest can also be evaluated against the total number of InflaRx N-V shares, or, against the total number of tradable InflaRx N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InflaRx N-V's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 InflaRx N-V shares in existence, roughly 10 shares are currently held short) or 0.0176% of the tradable shares (for every 100,000 tradable InflaRx N-V shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InflaRx N-V.
Find out more about how you can short InflaRx N-V stock.
We're not expecting InflaRx N-V to pay a dividend over the next 12 months.
Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $2.98 up to $9.6979. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 0.5145. This would suggest that InflaRx N-V's shares are less volatile than average (for this exchange).
InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.